HC Wainwright Has Negative View of Zymeworks FY2026 Earnings

Zymeworks Inc. (NASDAQ:ZYME) – Analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Zymeworks in a report released on Monday, August 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn $0.31 per share for the year, down from their prior forecast of $0.36. HC Wainwright has a “Buy” rating and a $51.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.25 per share. HC Wainwright also issued estimates for Zymeworks’ Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.42) EPS.

A number of other analysts also recently commented on ZYME. Stifel Nicolaus set a $46.00 price objective on shares of Zymeworks in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a report on Friday, July 17th. Truist Financial lifted their price target on shares of Zymeworks from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Friday. B. Riley Financial restated a “buy” rating and issued a $44.00 price target (up from $40.00) on shares of Zymeworks in a report on Monday. Finally, Citigroup reaffirmed a “buy” rating on shares of Zymeworks in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $40.75.

Zymeworks Stock Up 2.6%

Shares of ZYME opened at $24.16 on Tuesday. The company has a 50-day simple moving average of $23.98 and a 200-day simple moving average of $24.46. The company has a market capitalization of $1.71 billion, a PE ratio of -11.96 and a beta of 1.15. Zymeworks has a 52-week low of $11.86 and a 52-week high of $29.75.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Thursday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). The business had revenue of $4.59 million during the quarter, compared to analyst estimates of $4.54 million. Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. Zymeworks’s revenue was down 90.6% compared to the same quarter last year. During the same period last year, the business posted $0.03 EPS.

Institutional Trading of Zymeworks

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Zymeworks during the fourth quarter worth $2,338,000. Rubric Capital Management LP increased its stake in Zymeworks by 21.7% in the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after purchasing an additional 1,250,000 shares during the last quarter. Vanguard Group Inc. lifted its position in Zymeworks by 8.1% during the fourth quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock worth $61,315,000 after buying an additional 174,293 shares during the period. Pictet Asset Management Holding SA purchased a new position in Zymeworks during the fourth quarter worth about $1,966,000. Finally, SummitTX Capital L.P. boosted its stake in Zymeworks by 43.3% in the 1st quarter. SummitTX Capital L.P. now owns 321,427 shares of the company’s stock worth $8,049,000 after buying an additional 97,159 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Zymeworks announced that its board has approved a stock repurchase plan on Thursday, May 14th that allows the company to repurchase $125.00 million in shares. This repurchase authorization allows the company to reacquire up to 7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.